Fulcrum Therapeutics Inc. and Myokardia Inc. agreed to discover, develop and commercialize therapies for treating genetic cardiomyopathies, a deal spun out of two companies with a mutual appreciation of each other’s abilities as well as personal relations and networking, Fulcrum’s CEO told BioWorld.
With a phase IIb readout coming in the third quarter of 2020, Cambridge, Mass.-based Fulcrum Therapeutics Inc. might be set up for a win in facioscapulohumeral muscular dystrophy (FSHD), a genetic muscle disorder for which there’s no treatment.
Acceleron Pharma Inc. and Fulcrum Therapeutics Inc., two Cambridge, Mass.-based companies that have benefited from partnerships, agreed to an R&D collaboration and license agreement to identify small molecules for treating an undisclosed target in pulmonary disease.
